Literature DB >> 15268897

FGF23 is processed by proprotein convertases but not by PHEX.

Anna Benet-Pagès1, Bettina Lorenz-Depiereux, Hans Zischka, Kenneth E White, Michael J Econs, Tim M Strom.   

Abstract

X-linked hypophosphatemia (XLH) and autosomal dominant hypophosphatemic rickets (ADHR) are characterized by renal phosphate wasting, rickets, and osteomalacia. ADHR is caused by gain of function mutations in the fibroblast growth factor 23 gene (FGF23). During secretion, FGF23 is processed at the C-terminus between amino acids 179 and 180. The cleavage site is mutated in ADHR, preventing processing of FGF23. Here, we show that FGF23 is likely to be cleaved by subtilisin-like proprotein convertases (SPC) as cleavage can be inhibited by a specific SPC inhibitor in HEK293 cells. SPCs, which are widely expressed, were demonstrated to be also present in HEK293 cells as well as in osteoblasts. XLH is caused by loss of function mutations in the putative endopeptidase PHEX. It was tempting to speculate that FGF23 is a substrate of PHEX, but studies have been inconclusive so far. Here, we used a secreted form of PHEX (secPHEX) and tagged and untagged FGF23 constructs for co-incubation experiments. These experiments provided evidence against cleavage of intact FGF23(25-251) as well as of N-terminal (FGF23(25-179)) and C-terminal (FGF23(180-251)) fragments by the endopeptidase PHEX.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15268897     DOI: 10.1016/j.bone.2004.04.002

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  83 in total

Review 1.  Hereditary disorders of renal phosphate wasting.

Authors:  Amir S Alizadeh Naderi; Robert F Reilly
Journal:  Nat Rev Nephrol       Date:  2010-10-05       Impact factor: 28.314

Review 2.  Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism.

Authors:  L Darryl Quarles
Journal:  Nat Rev Endocrinol       Date:  2012-01-17       Impact factor: 43.330

Review 3.  Recent advances in renal phosphate handling.

Authors:  Emily G Farrow; Kenneth E White
Journal:  Nat Rev Nephrol       Date:  2010-02-23       Impact factor: 28.314

Review 4.  Endocrine functions of bone in mineral metabolism regulation.

Authors:  L Darryl Quarles
Journal:  J Clin Invest       Date:  2008-12-01       Impact factor: 14.808

Review 5.  Heritable and acquired disorders of phosphate metabolism: Etiologies involving FGF23 and current therapeutics.

Authors:  Erica L Clinkenbeard; Kenneth E White
Journal:  Bone       Date:  2017-01-31       Impact factor: 4.398

6.  Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans.

Authors:  Erik A Imel; Munro Peacock; Amie K Gray; Leah R Padgett; Siu L Hui; Michael J Econs
Journal:  J Clin Endocrinol Metab       Date:  2011-08-31       Impact factor: 5.958

Review 7.  The Causes of Hypo- and Hyperphosphatemia in Humans.

Authors:  Eugénie Koumakis; Catherine Cormier; Christian Roux; Karine Briot
Journal:  Calcif Tissue Int       Date:  2020-04-13       Impact factor: 4.333

8.  Increased bone volume and correction of HYP mouse hypophosphatemia in the Klotho/HYP mouse.

Authors:  Catherine A Brownstein; Junhui Zhang; Althea Stillman; Bruce Ellis; Nancy Troiano; Douglas J Adams; Caren M Gundberg; Richard P Lifton; Thomas O Carpenter
Journal:  Endocrinology       Date:  2009-12-01       Impact factor: 4.736

9.  Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active.

Authors:  Takashi Shimada; Itaru Urakawa; Tamara Isakova; Yuji Yamazaki; Michael Epstein; Katherine Wesseling-Perry; Myles Wolf; Isidro B Salusky; Harald Jüppner
Journal:  J Clin Endocrinol Metab       Date:  2009-12-04       Impact factor: 5.958

10.  A case of familial tumoral calcinosis/hyperostosis-hyperphosphatemia syndrome due to a compound heterozygous mutation in GALNT3 demonstrating new phenotypic features.

Authors:  C E Dumitrescu; M H Kelly; A Khosravi; T C Hart; J Brahim; K E White; E G Farrow; M H Nathan; M D Murphey; M T Collins
Journal:  Osteoporos Int       Date:  2008-11-04       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.